PARSIPPANY, N.J. / Feb 13, 2024 / Business Wire / Zoetis Inc. (NYSE: ZTS) today reported its financial results for the fourth quarter and full year 2023 as well as provided full year guidance for 2024.
The company reported revenue of $2.2 billion for the fourth quarter of 2023, which was an increase of 8% compared with the fourth quarter of 2022, on both a reported and operational1 basis. Net income for the fourth quarter of 2023 was $525 million, or $1.14 per diluted share, an increase of 14% and 15%, respectively, on a reported basis.
Adjusted net income2 for the fourth quarter of 2023 was $569 million, or $1.24 per diluted share, an increase of 6% and 8%, respectively, on a reported and operational basis. Adjusted net income for the fourth quarter of 2023 excludes the net impact of $44 million for purchase accounting adjustments, acquisition-related costs and certain significant items.
For full year 2023, the company reported revenue of $8.5 billion, an increase of 6% compared with full year 2022. On an operational basis, revenue for full year 2023 increased 7%, excluding the impact of foreign currency. Net income for full year 2023 was $2.3 billion, or $5.07 per diluted share, an increase of 11% and 13%, respectively, on a reported basis.
Adjusted net income for full year 2023 was $2.5 billion, or $5.32 per diluted share, an increase of 7% and 9%, respectively, on a reported and operational basis. Adjusted net income for full year 2023 excludes the net impact of $113 million for purchase accounting adjustments, acquisition-related costs and certain significant items.
EXECUTIVE COMMENTARY
“Zoetis delivered another strong performance in 2023 thanks to our diverse portfolio across markets and species and our dedicated colleagues,” said Kristin Peck, Chief Executive Officer of Zoetis. “We grew revenue 7% operationally, driven by our innovative companion animal franchises across pain, dermatology and parasiticides. We also grew our adjusted net income 7% operationally, while continuing to support investments in R&D, supply chain, and commercial excellence capabilities that will drive our next phase of growth.”
“We are excited by the momentum of Librela in the U.S. and around the world as we work to build our next billion-dollar franchise. In addition to OA pain, we are well-positioned for growth in our other key franchises, including dermatology, parasiticides and diagnostics, and will continue to invest in solutions that will shape and expand the future of animal health. We are committed to continuing our track record of innovation and growing faster than the market, even during times of global uncertainty, and are guiding to full-year operational growth of 7% to 9% in revenue in 2024,” said Peck.
QUARTERLY HIGHLIGHTS
Zoetis organizes and manages its commercial operations across two regional segments: United States (U.S.) and International. Within these segments, the company delivers a diverse portfolio of products for companion animals and livestock, tailored to local trends and customer needs. In the fourth quarter of 2023:
INVESTMENTS IN GROWTH
Zoetis continues to advance innovation and care for animals across the globe. Since its last quarterly earnings announcement, Solensia (frunevetmab injection), the first injectable monoclonal antibody for the alleviation of pain associated with osteoarthritis in cats, received approval in Brazil. Additionally, Simparica Trio (sarolaner/moxidectin/pyrantel), the company’s triple combination oral parasiticide for dogs, was approved in China. The company expanded its Vetscan Imagyst™ diagnostics platform in the U.S. to include new applications for artificial intelligence (AI) urine sediment analysis for dogs and cats.
On the livestock side of the business, Zoetis received approval in Mexico for Poulvac® Procerta® HVT-IBD-ND, a part of the company’s recombinant vector vaccine portfolio for poultry, which provides early, robust protection against Marek’s, infectious bursal and Newcastle disease viruses with one dose. Poulvac Procerta HVT-IBD, which provides protection against Marek’s and infectious bursal viruses, was approved in the EU.
Zoetis also continues to grow key product franchises through additional claim extensions in major markets. In the fourth quarter, Simparica Trio received approval in Japan for claims related to efficacy against sarcoptic and demodectic manges. Revolution® Plus (selamectin/sarolaner), the company’s topical combination product that treats ticks, fleas, ear mites, lice and gastrointestinal worms and prevents heartworm disease in cats, received approval in the U.S. for claims related to the treatment and control of lone star tick infestations, making it the only parasiticide for cats on the market to defend against four types of ticks.
FINANCIAL GUIDANCE
Zoetis is providing full year 2024 guidance, which includes:
This guidance reflects foreign exchange rates as of late January 2024. Additional details on guidance are included in the financial tables and will be discussed on the company's conference call this morning.
WEBCAST & CONFERENCE CALL DETAILS
Zoetis will host a webcast and conference call at 8:30 a.m. (ET) today, during which company executives will review fourth quarter and full year 2023 results, discuss financial guidance and respond to questions from financial analysts. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. A replay of the webcast will be archived and made available on February 13, 2024.
About Zoetis
As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers and ranchers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $8.5 billion in 2023 with approximately 14,100 employees. For more information, visit www.zoetis.com.
1 Operational growth (a non-GAAP financial measure) is defined as growth excluding the impact of foreign exchange.
2 Adjusted net income and its components and adjusted diluted earnings per share (non-GAAP financial measures) are defined as reported net income and reported diluted earnings per share, excluding purchase accounting adjustments, acquisition-related costs and certain significant items.
DISCLOSURE NOTICES
Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to: business plans or prospects, future operating or financial performance, future guidance, future operating models; R&D costs; timing and likelihood of success; expectations regarding products, product approvals or products under development and expected timing of product launches; disruptions in our global supply chain; expectations regarding the performance of acquired companies and our ability to integrate new businesses; expectations regarding the financial impact of acquisitions; future use of cash, dividend payments and share repurchases; tax rates and tax regimes and any changes thereto; and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our most recent Annual Report on Form 10-K, including in the sections thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis.
Use of Non-GAAP Financial Measures: We use non-GAAP financial measures, such as adjusted net income, adjusted diluted earnings per share and operational results (which exclude the impact of foreign exchange), to assess and analyze our results and trends and to make financial and operational decisions. We believe these non-GAAP financial measures are also useful to investors because they provide greater transparency regarding our operating performance. The non-GAAP financial measures included in this press release should not be considered alternatives to measurements required by GAAP, such as net income, operating income, and earnings per share, and should not be considered measures of liquidity. These non-GAAP financial measures are unlikely to be comparable with non-GAAP information provided by other companies. Reconciliations of non-GAAP financial measures and the most directly comparable GAAP financial measures are included in the tables accompanying this press release and are posted on our website at www.zoetis.com.
Internet Posting of Information: We routinely post information that may be important to investors on the 'Investor Relations' section of our website at www.zoetis.com, as well as on LinkedIn, Facebook, X (formerly Twitter) and YouTube. We encourage investors and potential investors to consult our website regularly and to follow us on social media for company news and information.
ZOETIS INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME(a) (UNAUDITED) (millions of dollars, except per share data) | |||||||||||||||||||||
| Three Months Ended December 31, |
| % Change |
| Twelve Months Ended December 31, |
| % Change | ||||||||||||||
|
| 2023 |
|
|
| 2022 |
|
|
|
| 2023 |
|
|
| 2022 |
|
| ||||
Revenue | $ | 2,213 |
|
| $ | 2,040 |
|
| 8 |
|
| $ | 8,544 |
|
| $ | 8,080 |
|
| 6 |
|
Costs and expenses: |
|
|
|
|
|
|
|
|
|
|
| ||||||||||
Cost of sales |
| 728 |
|
|
| 653 |
|
| 11 |
|
|
| 2,561 |
|
|
| 2,454 |
|
| 4 |
|
Selling, general and administrative expenses |
| 565 |
|
|
| 514 |
|
| 10 |
|
|
| 2,151 |
|
|
| 2,009 |
|
| 7 |
|
Research and development expenses |
| 174 |
|
|
| 148 |
|
| 18 |
|
|
| 614 |
|
|
| 539 |
|
| 14 |
|
Amortization of intangible assets |
| 37 |
|
|
| 35 |
|
| 6 |
|
|
| 149 |
|
|
| 150 |
|
| (1 | ) |
Restructuring charges and certain acquisition-related costs |
| 8 |
|
|
| 2 |
|
| * |
|
| 53 |
|
|
| 11 |
|
| * | ||
Interest expense |
| 59 |
|
|
| 62 |
|
| (5 | ) |
|
| 239 |
|
|
| 221 |
|
| 8 |
|
Other (income)/deductions–net |
| (8 | ) |
|
| 34 |
|
| * |
|
| (159 | ) |
|
| 40 |
|
| * | ||
Income before provision for taxes on income |
| 650 |
|
|
| 592 |
|
| 10 |
|
|
| 2,936 |
|
|
| 2,656 |
|
| 11 |
|
Provision for taxes on income |
| 127 |
|
|
| 132 |
|
| (4 | ) |
|
| 596 |
|
|
| 545 |
|
| 9 |
|
Net income before allocation to noncontrolling interests |
| 523 |
|
|
| 460 |
|
| 14 |
|
|
| 2,340 |
|
|
| 2,111 |
|
| 11 |
|
Less: Net loss attributable to noncontrolling interests |
| (2 | ) |
|
| (1 | ) |
| * |
|
| (4 | ) |
|
| (3 | ) |
| 33 |
| |
Net income attributable to Zoetis | $ | 525 |
|
| $ | 461 |
|
| 14 |
|
| $ | 2,344 |
|
| $ | 2,114 |
|
| 11 |
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||
Earnings per share—basic | $ | 1.14 |
|
| $ | 0.99 |
|
| 15 |
|
| $ | 5.08 |
|
| $ | 4.51 |
|
| 13 |
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||
Earnings per share—diluted | $ | 1.14 |
|
| $ | 0.99 |
|
| 15 |
|
| $ | 5.07 |
|
| $ | 4.49 |
|
| 13 |
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||
Weighted-average shares used to calculate earnings per share |
|
|
|
|
|
|
|
|
|
|
| ||||||||||
Basic |
| 459.0 |
|
|
| 465.6 |
|
|
|
|
| 461.2 |
|
|
| 468.9 |
|
|
| ||
Diluted |
| 460.1 |
|
|
| 466.8 |
|
|
|
|
| 462.3 |
|
|
| 470.4 |
|
|
| ||
(a) The Condensed Consolidated Statements of Income present the three and twelve months ended December 31, 2023 and 2022. Subsidiaries operating outside the U.S. are included for the three and twelve months ended November 30, 2023 and 2022. | |||||||||||||||||||||
* Calculation not meaningful. | |||||||||||||||||||||
ZOETIS INC. RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION CERTAIN LINE ITEMS (UNAUDITED) (millions of dollars, except per share data) | |||||||||||||||||||
| Three Months Ended December 31, 2023 | ||||||||||||||||||
| GAAP Reported(a) |
| Purchase Accounting Adjustments |
| Acquisition- Related Costs(1) |
| Certain Significant Items(2) |
| Non-GAAP Adjusted(b) | ||||||||||
Cost of sales | $ | 728 |
|
| $ | — |
|
| $ | — |
|
| $ | (1 | ) |
| $ | 727 |
|
Gross profit |
| 1,485 |
|
|
| — |
|
|
| — |
|
|
| 1 |
|
|
| 1,486 |
|
Selling, general and administrative expenses |
| 565 |
|
|
| (3 | ) |
|
| — |
|
|
| — |
|
|
| 562 |
|
Research and development expenses |
| 174 |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| 174 |
|
Amortization of intangible assets |
| 37 |
|
|
| (32 | ) |
|
| — |
|
|
| — |
|
|
| 5 |
|
Restructuring charges and certain acquisition-related costs |
| 8 |
|
|
| — |
|
|
| (1 | ) |
|
| (7 | ) |
|
| — |
|
Other (income)/deductions–net |
| (8 | ) |
|
| — |
|
|
| — |
|
|
| (4 | ) |
|
| (12 | ) |
Income before provision for taxes on income |
| 650 |
|
|
| 35 |
|
|
| 1 |
|
|
| 12 |
|
|
| 698 |
|
Provision for taxes on income |
| 127 |
|
|
| 6 |
|
|
| 1 |
|
|
| (3 | ) |
|
| 131 |
|
Net income attributable to Zoetis |
| 525 |
|
|
| 29 |
|
|
| — |
|
|
| 15 |
|
|
| 569 |
|
Earnings per common share attributable to Zoetis–diluted |
| 1.14 |
|
|
| 0.07 |
|
|
| — |
|
|
| 0.03 |
|
|
| 1.24 |
|
|
|
|
|
|
|
|
|
|
| ||||||||||
| Three Months Ended December 31, 2022 | ||||||||||||||||||
| GAAP Reported(a) |
| Purchase Accounting Adjustments |
| Acquisition- Related Costs(1) |
| Certain Significant Items(2) |
| Non-GAAP Adjusted(b) | ||||||||||
Cost of sales | $ | 653 |
|
| $ | (3 | ) |
| $ | — |
|
| $ | — |
|
| $ | 650 |
|
Gross profit |
| 1,387 |
|
|
| 3 |
|
|
| — |
|
|
| — |
|
|
| 1,390 |
|
Selling, general and administrative expenses |
| 514 |
|
|
| (7 | ) |
|
| — |
|
|
| — |
|
|
| 507 |
|
Research and development expenses |
| 148 |
|
|
| (1 | ) |
|
| — |
|
|
| — |
|
|
| 147 |
|
Amortization of intangible assets |
| 35 |
|
|
| (29 | ) |
|
| — |
|
|
| — |
|
|
| 6 |
|
Restructuring charges and certain acquisition-related costs |
| 2 |
|
|
| — |
|
|
| (1 | ) |
|
| (1 | ) |
|
| — |
|
Other (income)/deductions–net |
| 34 |
|
|
| — |
|
|
| — |
|
|
| (45 | ) |
|
| (11 | ) |
Income before provision for taxes on income |
| 592 |
|
|
| 40 |
|
|
| 1 |
|
|
| 46 |
|
|
| 679 |
|
Provision for taxes on income |
| 132 |
|
|
| 12 |
|
|
| — |
|
|
| (3 | ) |
|
| 141 |
|
Net income attributable to Zoetis |
| 461 |
|
|
| 28 |
|
|
| 1 |
|
|
| 49 |
|
|
| 539 |
|
Earnings per common share attributable to Zoetis–diluted |
| 0.99 |
|
|
| 0.06 |
|
|
| — |
|
|
| 0.10 |
|
|
| 1.15 |
|
(a) The Condensed Consolidated Statements of Income present the three months ended December 31, 2023 and 2022. Subsidiaries operating outside the U.S. are included for the three months ended November 30, 2023 and 2022. | |||||||||||||||||||
| (b) Non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS. Despite the importance of these measures to management in goal setting and performance measurement, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable to the calculation of similar measures of other companies. Non-GAAP adjusted net income and its components, and non-GAAP adjusted diluted EPS are presented solely to permit investors to more fully understand how management assesses performance. | |||||||||||||||||||
See Notes to Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for notes (1) and (2). | |||||||||||||||||||
ZOETIS INC. RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION CERTAIN LINE ITEMS (UNAUDITED) (millions of dollars, except per share data) | |||||||||||||||||||
| Twelve Months Ended December 31, 2023 | ||||||||||||||||||
| GAAP Reported(a) |
| Purchase Accounting Adjustments |
| Acquisition- Related Costs(1) |
| Certain Significant Items(2) |
| Non-GAAP Adjusted(b) | ||||||||||
Cost of sales | $ | 2,561 |
|
| $ | (10 | ) |
| $ | — |
|
| $ | (3 | ) |
| $ | 2,548 |
|
Gross profit |
| 5,983 |
|
|
| 10 |
|
|
| — |
|
|
| 3 |
|
|
| 5,996 |
|
Selling, general and administrative expenses |
| 2,151 |
|
|
| (21 | ) |
|
| — |
|
|
| — |
|
|
| 2,130 |
|
Research and development expenses |
| 614 |
|
|
| (1 | ) |
|
| — |
|
|
| — |
|
|
| 613 |
|
Amortization of intangible assets |
| 149 |
|
|
| (127 | ) |
|
| — |
|
|
| — |
|
|
| 22 |
|
Restructuring charges and certain acquisition-related costs |
| 53 |
|
|
| — |
|
|
| (9 | ) |
|
| (44 | ) |
|
| — |
|
Other (income)/deductions–net |
| (159 | ) |
|
| — |
|
|
| — |
|
|
| 80 |
|
|
| (79 | ) |
Income before provision for taxes on income |
| 2,936 |
|
|
| 159 |
|
|
| 9 |
|
|
| (33 | ) |
|
| 3,071 |
|
Provision for taxes on income |
| 596 |
|
|
| 32 |
|
|
| 2 |
|
|
| (12 | ) |
|
| 618 |
|
Net income attributable to Zoetis |
| 2,344 |
|
|
| 127 |
|
|
| 7 |
|
|
| (21 | ) |
|
| 2,457 |
|
Earnings per common share attributable to Zoetis–diluted |
| 5.07 |
|
|
| 0.28 |
|
|
| 0.02 |
|
|
| (0.05 | ) |
|
| 5.32 |
|
|
|
|
|
|
|
|
|
|
| ||||||||||
| Twelve Months Ended December 31, 2022 | ||||||||||||||||||
| GAAP Reported(a) |
| Purchase Accounting Adjustments |
| Acquisition- Related Costs(1) |
| Certain Significant Items(2) |
| Non-GAAP Adjusted(b) | ||||||||||
Cost of sales | $ | 2,454 |
|
| $ | (6 | ) |
| $ | — |
|
| $ | (8 | ) |
| $ | 2,440 |
|
Gross profit |
| 5,626 |
|
|
| 6 |
|
|
| — |
|
|
| 8 |
|
|
| 5,640 |
|
Selling, general and administrative expenses |
| 2,009 |
|
|
| (29 | ) |
|
| — |
|
|
| — |
|
|
| 1,980 |
|
Research and development expenses |
| 539 |
|
|
| (1 | ) |
|
| — |
|
|
| — |
|
|
| 538 |
|
Amortization of intangible assets |
| 150 |
|
|
| (124 | ) |
|
| — |
|
|
| — |
|
|
| 26 |
|
Restructuring charges and certain acquisition-related costs |
| 11 |
|
|
| — |
|
|
| (5 | ) |
|
| (6 | ) |
|
| — |
|
Other (income)/deductions–net |
| 40 |
|
|
| — |
|
|
| — |
|
|
| (42 | ) |
|
| (2 | ) |
Income before provision for taxes on income |
| 2,656 |
|
|
| 160 |
|
|
| 5 |
|
|
| 56 |
|
|
| 2,877 |
|
Provision for taxes on income |
| 545 |
|
|
| 40 |
|
|
| 1 |
|
|
| (3 | ) |
|
| 583 |
|
Net income attributable to Zoetis |
| 2,114 |
|
|
| 120 |
|
|
| 4 |
|
|
| 59 |
|
|
| 2,297 |
|
Earnings per common share attributable to Zoetis–diluted |
| 4.49 |
|
|
| 0.26 |
|
|
| 0.01 |
|
|
| 0.12 |
|
|
| 4.88 |
|
(a) The Condensed Consolidated Statements of Income present the twelve months ended December 31, 2023 and 2022. Subsidiaries operating outside the U.S. are included for the twelve months ended November 30, 2023 and 2022. | |||||||||||||||||||
(b) Non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS. Despite the importance of these measures to management in goal setting and performance measurement, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable to the calculation of similar measures of other companies. Non-GAAP adjusted net income and its components, and non-GAAP adjusted diluted EPS are presented solely to permit investors to more fully understand how management assesses performance. | |||||||||||||||||||
See Notes to Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for notes (1) and (2). | |||||||||||||||||||
ZOETIS INC. NOTES TO RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION CERTAIN LINE ITEMS (UNAUDITED) (millions of dollars) | ||||||||||||
| (1) Acquisition-related costs include the following: | ||||||||||||
| Three Months Ended December 31, |
| Twelve Months Ended December 31, | |||||||||
|
| 2023 |
|
| 2022 |
|
| 2023 |
|
| 2022 | |
Transaction costs(a) | $ | — |
| $ | 1 |
| $ | 4 |
| $ | 1 | |
Integration costs(b) |
| — |
|
| — |
|
| 3 |
|
| 4 | |
Restructuring charges(c) |
| 1 |
|
| — |
|
| 2 |
|
| — | |
Total acquisition-related costs—pre-tax |
| 1 |
|
| 1 |
|
| 9 |
|
| 5 | |
Income taxes(d) |
| 1 |
|
| — |
|
| 2 |
|
| 1 | |
Total acquisition-related costs—net of tax | $ | — |
| $ | 1 |
| $ | 7 |
| $ | 4 | |
(a) Transaction costs represent external costs directly related to acquiring businesses and primarily includes expenditures for banking, legal, accounting and other similar services. Included in Restructuring charges and certain acquisition-related costs. | ||||||||||||
(b) Integration costs represent external, incremental costs directly related to integrating acquired businesses and primarily include expenditures for consulting and the integration of systems and processes. Included in Restructuring charges and certain acquisition-related costs. | ||||||||||||
(c) Restructuring charges represent employee termination costs, included in Restructuring charges and certain acquisition-related costs. | ||||||||||||
(d) Included in Provision for taxes on income. Income taxes include the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction's applicable tax rate. | ||||||||||||
| (2) Certain significant items include the following: | ||||||||||||||||
| Three Months Ended December 31, |
| Twelve Months Ended December 31, | |||||||||||||
|
| 2023 |
|
|
| 2022 |
|
|
| 2023 |
|
|
| 2022 |
| |
Other restructuring charges and cost-reduction/productivity initiatives(a) | $ | 8 |
|
| $ | 1 |
|
| $ | 44 |
|
| $ | 8 |
| |
Certain asset impairment charges(b) |
| 3 |
|
|
| 41 |
|
|
| 24 |
|
|
| 47 |
| |
Net gain on sale of businesses(c) |
| — |
|
|
| — |
|
|
| (101 | ) |
|
| — |
| |
Other |
| 1 |
|
|
| 4 |
|
|
| — |
|
|
| 1 |
| |
Total certain significant items—pre-tax |
| 12 |
|
|
| 46 |
|
|
| (33 | ) |
|
| 56 |
| |
Income taxes(d) |
| (3 | ) |
|
| (3 | ) |
|
| (12 | ) |
|
| (3 | ) | |
Total certain significant items—net of tax | $ | 15 |
|
| $ | 49 |
|
| $ | (21 | ) |
| $ | 59 |
| |
(a) For the three and twelve months ended December 31, 2023, primarily represents employee termination and exit costs related to organizational structure refinements and other cost-reduction and productivity initiatives, primarily included in Restructuring charges and certain acquisition-related costs. | ||||||||||||||||
For the twelve months ended December 31, 2022, primarily represents employee termination and exit costs associated with cost-reduction and productivity initiatives in certain international markets, included in Restructuring charges and certain acquisition-related costs, as well as product transfer costs, included in Cost of sales. | ||||||||||||||||
(b) For the twelve months ended December 31, 2023, primarily represents certain asset impairment charges related to our precision animal health and diagnostics businesses, primarily included in Other (income)/deductions–net. | ||||||||||||||||
For the three and twelve months ended December 31, 2022, primarily represents asset impairment charges related to customer relationships, developed technology rights and property, plant and equipment in our diagnostics, poultry, cattle and swine businesses, included in Other (income)/deductions-net. | ||||||||||||||||
(c) Primarily represents a net gain on the sale of a majority interest in our pet insurance business, included in Other (income)/deductions–net. | ||||||||||||||||
(d) Included in Provision for taxes on income. Income taxes include the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction's applicable tax rate. Income taxes in Certain significant items also includes:
| ||||||||||||||||
ZOETIS INC. ADJUSTED SELECTED COSTS AND EXPENSES(a) (UNAUDITED) (millions of dollars) | ||||||||||||||||||
|
| Three Months Ended December 31, |
| % Change | ||||||||||||||
|
|
| 2023 |
|
|
| 2022 |
|
| Total |
|
| Foreign Exchange |
| Operational(b) | |||
Adjusted cost of sales |
| $ | 727 |
|
| $ | 650 |
|
| 12 | % |
|
| 3 | % |
| 9 | % |
As a percent of revenue |
|
| 32.9 | % |
|
| 31.9 | % |
| NA |
|
| NA |
| NA | |||
Adjusted SG&A expenses |
|
| 562 |
|
|
| 507 |
|
| 11 | % |
|
| 1 | % |
| 10 | % |
Adjusted R&D expenses |
|
| 174 |
|
|
| 147 |
|
| 18 | % |
|
| 1 | % |
| 17 | % |
Adjusted net income attributable to Zoetis |
|
| 569 |
|
|
| 539 |
|
| 6 | % |
|
| — | % |
| 6 | % |
|
|
|
|
| ||||||||||||||
|
| Twelve Months Ended December 31, |
| % Change | ||||||||||||||
|
|
| 2023 |
|
|
| 2022 |
|
| Total |
|
| Foreign Exchange |
| Operational(b) | |||
Adjusted cost of sales |
| $ | 2,548 |
|
| $ | 2,440 |
|
| 4 | % |
|
| (4 | )% |
| 8 | % |
As a percent of revenue |
|
| 29.8 | % |
|
| 30.2 | % |
| NA |
|
| NA |
| NA | |||
Adjusted SG&A expenses |
|
| 2,130 |
|
|
| 1,980 |
|
| 8 | % |
|
| (1 | )% |
| 9 | % |
Adjusted R&D expenses |
|
| 613 |
|
|
| 538 |
|
| 14 | % |
|
| — | % |
| 14 | % |
Adjusted net income attributable to Zoetis |
|
| 2,457 |
|
|
| 2,297 |
|
| 7 | % |
|
| — | % |
| 7 | % |
|
|
|
|
|
|
|
|
|
|
|
| |||||||
(a) Adjusted cost of sales, adjusted selling, general, and administrative (SG&A) expenses, adjusted research and development (R&D) expenses, and adjusted net income (non-GAAP financial measures) are defined as the corresponding reported U.S. GAAP income statement line items excluding purchase accounting adjustments, acquisition-related costs, and certain significant items. These adjusted income statement line item measures are not, and should not be viewed as, substitutes for the corresponding U.S. GAAP line items. The corresponding GAAP line items and reconciliations of reported to adjusted information are provided in Condensed Consolidated Statements of Income and Reconciliation of GAAP Reported to Non-GAAP Adjusted Information. | ||||||||||||||||||
(b) Operational growth (a non-GAAP financial measure) is defined as growth excluding the impact of foreign exchange. | ||||||||||||||||||
ZOETIS INC. 2024 GUIDANCE | |
Selected Line Items (millions of dollars, except per share amounts) | Full Year 2024 |
Revenue | $9,075 to $9,225 |
Operational growth(a) | 7% to 9% |
Adjusted cost of sales as a percentage of revenue(b) | Approximately 29.5% |
Adjusted SG&A expenses(b) | $2,170 to $2,220 |
Adjusted R&D expenses(b) | $665 to $675 |
Adjusted interest expense and other (income)/deductions-net(b) | Approximately $210 |
Effective tax rate on adjusted income(b) | 20.0% to 21.0% |
Adjusted diluted EPS(b) | $5.74 to $5.84 |
Adjusted net income(b) | $2,650 to $2,700 |
Operational growth(a)(c) | 9% to 11% |
Certain significant items and acquisition-related costs(d) | $70 - $75 |
The guidance reflects foreign exchange rates as of late January 2024. | |
Reconciliations of 2024 reported guidance to 2024 adjusted guidance follows: | |||||
(millions of dollars, except per share amounts) | Reported | Certain significant items and acquisition-related costs(d) | Purchase accounting | Adjusted(b) | |
Cost of sales as a percentage of revenue | ~ 29.6% |
| ~ (0.1%) | ~ 29.5% | |
SG&A expenses | $2,191 to $2,241 |
| ~ $(21) | $2,170 to $2,220 | |
R&D expenses | $666 to $676 |
| ~ $(1) | $665 to $675 | |
Interest expense and other (income)/deductions | ~ $240 | ~ $30 |
| ~ $270 | |
Effective tax rate | 20.0% to 21.0% |
|
| 20.0% to 21.0% | |
Diluted EPS | $5.34 to $5.44 | ~ $0.16 | ~ $0.24 | $5.74 to $5.84 | |
Net income attributable to Zoetis | $2,468 to $2,513 | $70 - $75 | ~ $112 | $2,650 to $2,700 | |
(a) Operational growth (a non-GAAP financial measure) excludes the impact of foreign exchange. | |||||
(b) Adjusted net income and its components and adjusted diluted EPS are defined as reported U.S. GAAP net income and its components and reported diluted EPS excluding purchase accounting adjustments, acquisition-related costs and certain significant items. Adjusted cost of sales, adjusted SG&A expenses, adjusted R&D expenses, and adjusted interest expense and other (income)/deductions-net are income statement line items prepared on the same basis, and, therefore, components of the overall adjusted income measure. Despite the importance of these measures to management in goal setting and performance measurement, adjusted net income and its components and adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, adjusted net income and its components and adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable to the calculation of similar measures of other companies. Adjusted net income and its components and adjusted diluted EPS are presented solely to permit investors to more fully understand how management assesses performance. Adjusted net income and its components and adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS. | |||||
(c) We do not provide a reconciliation of forward-looking non-GAAP adjusted net income operational growth to the most directly comparable U.S. GAAP reported financial measure because we are unable to calculate with reasonable certainty the foreign exchange impact of unusual gains and losses, acquisition-related expenses, potential future asset impairments and other certain significant items, without unreasonable effort. The foreign exchange impacts of these items are uncertain, depend on various factors, and could have a material impact on U.S. GAAP reported results for the guidance period. | |||||
(d) Primarily includes certain nonrecurring costs related to acquisitions and other charges. | |||||
ZOETIS INC. CONSOLIDATED REVENUE BY SEGMENT(a) AND SPECIES (UNAUDITED) (millions of dollars) | |||||||||||||||
|
| Three Months Ended December 31, |
| % Change | |||||||||||
|
|
| 2023 |
|
| 2022 |
| Total |
| Foreign Exchange |
| Operational(b) | |||
Revenue: |
|
|
|
|
|
|
|
|
|
| |||||
Companion Animal |
| $ | 1,448 |
| $ | 1,303 |
| 1 | % |
| 1 | % |
| 10 | % |
Livestock |
|
| 745 |
|
| 710 |
| 5 | % |
| (1 | )% |
| 6 | % |
Contract Manufacturing & Human Health |
|
| 20 |
|
| 27 |
| (26 | )% |
| 1 | % |
| (27 | )% |
Total Revenue |
| $ | 2,213 |
| $ | 2,040 |
| 8 | % |
| — | % |
| 8 | % |
|
|
|
|
|
|
|
|
|
|
| |||||
U.S. |
|
|
|
|
|
|
|
|
|
| |||||
Companion Animal |
| $ | 941 |
| $ | 853 |
| 10 | % |
| — | % |
| 10 | % |
Livestock |
|
| 270 |
|
| 259 |
| 4 | % |
| — | % |
| 4 | % |
Total U.S. Revenue |
| $ | 1,211 |
| $ | 1,112 |
| 9 | % |
| — | % |
| 9 | % |
|
|
|
|
|
|
|
|
|
|
| |||||
International |
|
|
|
|
|
|
|
|
|
| |||||
Companion Animal |
| $ | 507 |
| $ | 450 |
| 13 | % |
| 3 | % |
| 10 | % |
Livestock |
|
| 475 |
|
| 451 |
| 5 | % |
| (2 | )% |
| 7 | % |
Total International Revenue |
| $ | 982 |
| $ | 901 |
| 9 | % |
| 1 | % |
| 8 | % |
|
|
|
|
|
|
|
|
|
|
| |||||
Companion Animal: |
|
|
|
|
|
|
|
|
|
| |||||
Dogs and Cats |
| $ | 1,360 |
| $ | 1,224 |
| 11 | % |
| 1 | % |
| 10 | % |
Horses |
|
| 88 |
|
| 79 |
| 11 | % |
| — | % |
| 11 | % |
Total Companion Animal Revenue |
| $ | 1,448 |
| $ | 1,303 |
| 11 | % |
| 1 | % |
| 10 | % |
|
|
|
|
|
|
|
|
|
|
| |||||
Livestock: |
|
|
|
|
|
|
|
|
|
| |||||
Cattle |
| $ | 401 |
| $ | 377 |
| 6 | % |
| (1 | )% |
| 7 | % |
Swine |
|
| 139 |
|
| 138 |
| 1 | % |
| 1 | % |
| — | % |
Poultry |
|
| 127 |
|
| 115 |
| 10 | % |
| (3 | )% |
| 13 | % |
Fish |
|
| 62 |
|
| 61 |
| 2 | % |
| (3 | )% |
| 5 | % |
Sheep and other |
|
| 16 |
|
| 19 |
| (16 | )% |
| 1 | % |
| (17 | )% |
Total Livestock Revenue |
| $ | 745 |
| $ | 710 |
| 5 | % |
| (1 | )% |
| 6 | % |
(a) For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K. | |||||||||||||||
(b) Operational revenue growth (a non-GAAP financial measure) is defined as revenue growth excluding the impact of foreign exchange. | |||||||||||||||
ZOETIS INC. CONSOLIDATED REVENUE BY SEGMENT(a) AND SPECIES (UNAUDITED) (millions of dollars) | ||||||||||||||||
|
| Twelve Months Ended December 31, |
| % Change | ||||||||||||
|
|
| 2023 |
|
| 2022 |
| Total |
|
| Foreign Exchange |
| Operational(b) | |||
Revenue: |
|
|
|
|
|
|
|
|
|
|
| |||||
Companion Animal |
| $ | 5,576 |
| $ | 5,203 |
| 7 | % |
|
| (1 | )% |
| 8 | % |
Livestock |
|
| 2,890 |
|
| 2,791 |
| 4 | % |
|
| (2 | )% |
| 6 | % |
Contract Manufacturing & Human Health |
|
| 78 |
|
| 86 |
| (9 | )% |
|
| 1 | % |
| (10 | )% |
Total Revenue |
| $ | 8,544 |
| $ | 8,080 |
| 6 | % |
|
| (1 | )% |
| 7 | % |
|
|
|
|
|
|
|
|
|
|
|
| |||||
U.S. |
|
|
|
|
|
|
|
|
|
|
| |||||
Companion Animal |
| $ | 3,529 |
| $ | 3,341 |
| 6 | % |
|
| — | % |
| 6 | % |
Livestock |
|
| 1,026 |
|
| 972 |
| 6 | % |
|
| — | % |
| 6 | % |
Total U.S. Revenue |
| $ | 4,555 |
| $ | 4,313 |
| 6 | % |
|
| — | % |
| 6 | % |
|
|
|
|
|
|
|
|
|
|
|
| |||||
International |
|
|
|
|
|
|
|
|
|
|
| |||||
Companion Animal |
| $ | 2,047 |
| $ | 1,862 |
| 10 | % |
|
| (2 | )% |
| 12 | % |
Livestock |
|
| 1,864 |
|
| 1,819 |
| 2 | % |
|
| (5 | )% |
| 7 | % |
Total International Revenue |
| $ | 3,911 |
| $ | 3,681 |
| 6 | % |
|
| (3 | )% |
| 9 | % |
|
|
|
|
|
|
|
|
|
|
|
| |||||
Companion Animal: |
|
|
|
|
|
|
|
|
|
|
| |||||
Dogs and Cats |
| $ | 5,291 |
| $ | 4,939 |
| 7 | % |
|
| (1 | )% |
| 8 | % |
Horses |
|
| 285 |
|
| 264 |
| 8 | % |
|
| (1 | )% |
| 9 | % |
Total Companion Animal Revenue |
| $ | 5,576 |
| $ | 5,203 |
| 7 | % |
|
| (1 | )% |
| 8 | % |
|
|
|
|
|
|
|
|
|
|
|
| |||||
Livestock: |
|
|
|
|
|
|
|
|
|
|
| |||||
Cattle |
| $ | 1,503 |
| $ | 1,440 |
| 4 | % |
|
| (3 | )% |
| 7 | % |
Swine |
|
| 543 |
|
| 565 |
| (4 | )% |
|
| (2 | )% |
| (2 | )% |
Poultry |
|
| 524 |
|
| 476 |
| 10 | % |
|
| (3 | )% |
| 13 | % |
Fish |
|
| 220 |
|
| 212 |
| 4 | % |
|
| (4 | )% |
| 8 | % |
Sheep and other |
|
| 100 |
|
| 98 |
| 2 | % |
|
| (6 | )% |
| 8 | % |
Total Livestock Revenue |
| $ | 2,890 |
| $ | 2,791 |
| 4 | % |
|
| (2 | )% |
| 6 | % |
(a) For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K. | ||||||||||||||||
(b) Operational revenue growth (a non-GAAP financial measure) is defined as revenue growth excluding the impact of foreign exchange. | ||||||||||||||||
ZOETIS INC. CONSOLIDATED REVENUE BY KEY INTERNATIONAL MARKETS (UNAUDITED) (millions of dollars) | ||||||||||||||||
|
| Three Months Ended December 31, |
| % Change | ||||||||||||
|
|
| 2023 |
|
| 2022 |
| Total |
|
| Foreign Exchange |
| Operational(a) | |||
Total International |
| $ | 982.1 |
| $ | 901.3 |
| 9 | % |
|
| 1 | % |
| 8 | % |
Australia |
|
| 75.0 |
|
| 64.2 |
| 17 | % |
|
| (2 | )% |
| 19 | % |
Brazil |
|
| 117.2 |
|
| 96.2 |
| 22 | % |
|
| 7 | % |
| 15 | % |
Canada |
|
| 71.1 |
|
| 65.2 |
| 9 | % |
|
| (2 | )% |
| 11 | % |
Chile |
|
| 31.4 |
|
| 34.8 |
| (10 | )% |
|
| 1 | % |
| (11 | )% |
China |
|
| 64.7 |
|
| 91.4 |
| (29 | )% |
|
| (1 | )% |
| (28 | )% |
France |
|
| 40.5 |
|
| 35.1 |
| 15 | % |
|
| 8 | % |
| 7 | % |
Germany |
|
| 54.1 |
|
| 44.0 |
| 23 | % |
|
| 8 | % |
| 15 | % |
Italy |
|
| 33.9 |
|
| 25.6 |
| 32 | % |
|
| 9 | % |
| 23 | % |
Japan |
|
| 38.0 |
|
| 36.1 |
| 5 | % |
|
| (4 | )% |
| 9 | % |
Mexico |
|
| 43.3 |
|
| 35.6 |
| 22 | % |
|
| 14 | % |
| 8 | % |
Spain |
|
| 27.3 |
|
| 21.3 |
| 28 | % |
|
| 9 | % |
| 19 | % |
United Kingdom |
|
| 67.9 |
|
| 60.3 |
| 13 | % |
|
| 9 | % |
| 4 | % |
Other Developed |
|
| 138.3 |
|
| 114.6 |
| 21 | % |
|
| 4 | % |
| 17 | % |
Other Emerging |
|
| 179.4 |
|
| 176.9 |
| 1 | % |
|
| (13 | )% |
| 14 | % |
|
|
|
|
|
|
|
|
|
|
|
| |||||
|
| Twelve Months Ended December 31, |
| % Change | ||||||||||||
|
|
| 2023 |
|
| 2022 |
| Total |
|
| Foreign Exchange |
| Operational(a) | |||
Total International |
| $ | 3,911.2 |
| $ | 3,680.8 |
| 6 | % |
|
| (3 | )% |
| 9 | % |
Australia |
|
| 322.7 |
|
| 288.7 |
| 12 | % |
|
| (5 | )% |
| 17 | % |
Brazil |
|
| 392.7 |
|
| 329.5 |
| 19 | % |
|
| 4 | % |
| 15 | % |
Canada |
|
| 254.6 |
|
| 237.5 |
| 7 | % |
|
| (5 | )% |
| 12 | % |
Chile |
|
| 140.2 |
|
| 141.1 |
| (1 | )% |
|
| 1 | % |
| (2 | )% |
China |
|
| 320.0 |
|
| 382.4 |
| (16 | )% |
|
| (5 | )% |
| (11 | )% |
France |
|
| 142.4 |
|
| 126.1 |
| 13 | % |
|
| 2 | % |
| 11 | % |
Germany |
|
| 202.4 |
|
| 176.3 |
| 15 | % |
|
| 3 | % |
| 12 | % |
Italy |
|
| 120.8 |
|
| 111.2 |
| 9 | % |
|
| 3 | % |
| 6 | % |
Japan |
|
| 157.9 |
|
| 173.1 |
| (9 | )% |
|
| (8 | )% |
| (1 | )% |
Mexico |
|
| 162.4 |
|
| 136.2 |
| 19 | % |
|
| 13 | % |
| 6 | % |
Spain |
|
| 121.6 |
|
| 117.8 |
| 3 | % |
|
| 1 | % |
| 2 | % |
United Kingdom |
|
| 277.0 |
|
| 234.5 |
| 18 | % |
|
| (1 | )% |
| 19 | % |
Other Developed |
|
| 512.2 |
|
| 468.4 |
| 9 | % |
|
| (2 | )% |
| 11 | % |
Other Emerging |
|
| 784.3 |
|
| 758.0 |
| 3 | % |
|
| (13 | )% |
| 16 | % |
(a) Operational revenue growth (a non-GAAP financial measure) is defined as revenue growth excluding the impact of foreign exchange. | ||||||||||||||||
ZOETIS INC. SEGMENT(a) EARNINGS (UNAUDITED) (millions of dollars) | ||||||||||||||||||
|
| Three Months Ended December 31, |
| % Change | ||||||||||||||
|
|
| 2023 |
|
|
| 2022 |
|
| Total |
|
| Foreign Exchange |
| Operational(b) | |||
U.S.: |
|
|
|
|
|
|
|
|
|
|
| |||||||
Revenue |
| $ | 1,211 |
|
| $ | 1,112 |
|
| 9 | % |
|
| — | % |
| 9 | % |
Cost of sales |
|
| 255 |
|
|
| 216 |
|
| 18 | % |
|
| — | % |
| 18 | % |
Gross profit |
|
| 956 |
|
|
| 896 |
|
| 7 | % |
|
| — | % |
| 7 | % |
Gross margin |
|
| 78.9 | % |
|
| 80.6 | % |
|
|
|
|
|
|
| |||
Operating expenses |
|
| 184 |
|
|
| 187 |
|
| (2 | )% |
|
| — | % |
| (2 | )% |
Other (income)/deductions-net |
|
| 6 |
|
|
| (12 | ) |
| * |
|
| * |
| * | |||
U.S. Earnings |
| $ | 766 |
|
| $ | 721 |
|
| 6 | % |
|
| — | % |
| 6 | % |
|
|
|
|
|
|
|
|
|
|
|
| |||||||
International: |
|
|
|
|
|
|
|
|
|
|
| |||||||
Revenue |
| $ | 982 |
|
| $ | 901 |
|
| 9 | % |
|
| 1 | % |
| 8 | % |
Cost of sales |
|
| 322 |
|
|
| 274 |
|
| 18 | % |
|
| 1 | % |
| 17 | % |
Gross profit |
|
| 660 |
|
|
| 627 |
|
| 5 | % |
|
| — | % |
| 5 | % |
Gross margin |
|
| 67.2 | % |
|
| 69.6 | % |
|
|
|
|
|
|
| |||
Operating expenses |
|
| 165 |
|
|
| 155 |
|
| 6 | % |
|
| 1 | % |
| 5 | % |
Other (income)/deductions-net |
|
| 1 |
|
|
| 2 |
|
| * |
|
| * |
| * | |||
International Earnings |
| $ | 494 |
|
| $ | 470 |
|
| 5 | % |
|
| — | % |
| 5 | % |
|
|
|
|
|
|
|
|
|
|
|
| |||||||
Total Reportable Segments |
| $ | 1,260 |
|
| $ | 1,191 |
|
| 6 | % |
|
| — | % |
| 6 | % |
|
|
|
|
|
|
|
|
|
|
|
| |||||||
Other business activities(c) |
|
| (142 | ) |
|
| (109 | ) |
| 30 | % |
|
|
|
|
| ||
Reconciling Items: |
|
|
|
|
|
|
|
|
|
|
| |||||||
Corporate(d) |
|
| (320 | ) |
|
| (302 | ) |
| 6 | % |
|
|
|
|
| ||
Purchase accounting adjustments(e) |
|
| (35 | ) |
|
| (40 | ) |
| (13 | )% |
|
|
|
|
| ||
Acquisition-related costs(f) |
|
| (1 | ) |
|
| (1 | ) |
| — | % |
|
|
|
|
| ||
Certain significant items(g) |
|
| (12 | ) |
|
| (46 | ) |
| (74 | )% |
|
|
|
|
| ||
Other unallocated(h) |
|
| (100 | ) |
|
| (101 | ) |
| (1 | )% |
|
|
|
|
| ||
Total Earnings(i) |
| $ | 650 |
|
| $ | 592 |
|
| 10 | % |
|
|
|
|
| ||
(a) For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K. | ||||||||||||||||||
(b) Operational growth (a non-GAAP financial measure) is defined as growth excluding the impact of foreign exchange. | ||||||||||||||||||
(c) Other business activities reflect the research and development costs managed by our research and development organization, as well as our contract manufacturing business and human health business. | ||||||||||||||||||
(d) Corporate includes, among other things, certain costs associated with information technology, administration expenses, interest income and expense, certain compensation costs and other costs not charged to our operating segments. | ||||||||||||||||||
(e) Purchase accounting adjustments include certain charges related to the amortization of fair value adjustments to inventory, intangible assets and property, plant and equipment not charged to our operating segments. | ||||||||||||||||||
(f) Acquisition-related costs include costs associated with acquiring and integrating newly acquired businesses, such as transaction costs and integration costs. | ||||||||||||||||||
(g) Certain significant items includes substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items primarily include certain asset impairment charges, restructuring charges and implementation costs associated with cost-reduction/productivity initiatives that are not associated with an acquisition and the impact of divestiture-related gains and losses. | ||||||||||||||||||
(h) Includes overhead expenses associated with our global manufacturing and supply operations not directly attributable to an operating segment, as well as certain procurement costs. | ||||||||||||||||||
(i) Defined as income before provision for taxes on income. | ||||||||||||||||||
* Calculation not meaningful. | ||||||||||||||||||
ZOETIS INC. SEGMENT(a) EARNINGS (UNAUDITED) (millions of dollars) | ||||||||||||||||||
|
| Twelve Months Ended December 31, |
| % Change | ||||||||||||||
|
|
| 2023 |
|
|
| 2022 |
|
| Total |
|
| Foreign Exchange |
| Operational(b) | |||
U.S.: |
|
|
|
|
|
|
|
|
|
|
| |||||||
Revenue |
| $ | 4,555 |
|
| $ | 4,313 |
|
| 6 | % |
|
| — | % |
| 6 | % |
Cost of sales |
|
| 900 |
|
|
| 803 |
|
| 12 | % |
|
| — | % |
| 12 | % |
Gross profit |
|
| 3,655 |
|
|
| 3,510 |
|
| 4 | % |
|
| — | % |
| 4 | % |
Gross margin |
|
| 80.2 | % |
|
| 81.4 | % |
|
|
|
|
|
|
| |||
Operating expenses |
|
| 786 |
|
|
| 765 |
|
| 3 | % |
|
| — | % |
| 3 | % |
Other (income)/deductions-net |
|
| 6 |
|
|
| (18 | ) |
| * |
|
| * |
| * | |||
U.S. Earnings |
| $ | 2,863 |
|
| $ | 2,763 |
|
| 4 | % |
|
| — | % |
| 4 | % |
|
|
|
|
|
|
|
|
|
|
|
| |||||||
International: |
|
|
|
|
|
|
|
|
|
|
| |||||||
Revenue |
| $ | 3,911 |
|
| $ | 3,681 |
|
| 6 | % |
|
| (3 | )% |
| 9 | % |
Cost of sales |
|
| 1,234 |
|
|
| 1,083 |
|
| 14 | % |
|
| (5 | )% |
| 19 | % |
Gross profit |
|
| 2,677 |
|
|
| 2,598 |
|
| 3 | % |
|
| (2 | )% |
| 5 | % |
Gross margin |
|
| 68.4 | % |
|
| 70.6 | % |
|
|
|
|
|
|
| |||
Operating expenses |
|
| 638 |
|
|
| 611 |
|
| 4 | % |
|
| (4 | )% |
| 8 | % |
Other (income)/deductions-net |
|
| 2 |
|
|
| (3 | ) |
| * |
|
| * |
| * | |||
International Earnings |
| $ | 2,037 |
|
| $ | 1,990 |
|
| 2 | % |
|
| (2 | )% |
| 4 | % |
|
|
|
|
|
|
|
|
|
|
|
| |||||||
Total Reportable Segments |
| $ | 4,900 |
|
| $ | 4,753 |
|
| 3 | % |
|
| (1 | )% |
| 4 | % |
|
|
|
|
|
|
|
|
|
|
|
| |||||||
Other business activities(c) |
|
| (496 | ) |
|
| (424 | ) |
| 17 | % |
|
|
|
|
| ||
Reconciling Items: |
|
|
|
|
|
|
|
|
|
|
| |||||||
Corporate(d) |
|
| (1,042 | ) |
|
| (1,073 | ) |
| (3 | )% |
|
|
|
|
| ||
Purchase accounting adjustments(e) |
|
| (159 | ) |
|
| (160 | ) |
| (1 | )% |
|
|
|
|
| ||
Acquisition-related costs(f) |
|
| (9 | ) |
|
| (5 | ) |
| 80 | % |
|
|
|
|
| ||
Certain significant items(g) |
|
| 33 |
|
|
| (56 | ) |
| * |
|
|
|
|
| |||
Other unallocated(h) |
|
| (291 | ) |
|
| (379 | ) |
| (23 | )% |
|
|
|
|
| ||
Total Earnings(i) |
| $ | 2,936 |
|
| $ | 2,656 |
|
| 11 | % |
|
|
|
|
| ||
(a) For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K. | ||||||||||||||||||
(b) Operational growth (a non-GAAP financial measure) is defined as growth excluding the impact of foreign exchange. | ||||||||||||||||||
(c) Other business activities reflect the research and development costs managed by our research and development organization, as well as our contract manufacturing business and human health business. | ||||||||||||||||||
(d) Corporate includes, among other things, certain costs associated with information technology, administration expenses, interest income and expense, certain compensation costs and other costs not charged to our operating segments. | ||||||||||||||||||
(e) Purchase accounting adjustments include certain charges related to the amortization of fair value adjustments to inventory, intangible assets and property, plant and equipment not charged to our operating segments. | ||||||||||||||||||
(f) Acquisition-related costs include costs associated with acquiring and integrating newly acquired businesses, such as transaction costs and integration costs. | ||||||||||||||||||
(g) Certain significant items includes substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items primarily include certain asset impairment charges, restructuring charges and implementation costs associated with cost-reduction/productivity initiatives that are not associated with an acquisition and the impact of divestiture-related gains and losses. | ||||||||||||||||||
(h) Includes overhead expenses associated with our global manufacturing and supply operations not directly attributable to an operating segment, as well as certain procurement costs. | ||||||||||||||||||
(i) Defined as income before provision for taxes on income. | ||||||||||||||||||
* Calculation not meaningful. | ||||||||||||||||||
| Last Trade: | US$175.67 |
| Daily Change: | 0.11 0.06 |
| Daily Volume: | 2,106,495 |
| Market Cap: | US$79.260B |
November 04, 2024 September 26, 2024 August 06, 2024 May 02, 2024 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
